title: Should all breast cancer patients with symptomatic bone metastases be treated with bisphosphonates? The case in support.
authors.affiliation: Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada. mark.clemons@sw.ca
authors.forename: M
authors.initials: M
authors.lastname: Clemons
mesh_terms: D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D008875:Middle Aged; D010347:Patient Care Planning; D011379:Prognosis
chemical_list: D004164:Diphosphonates